| Title | Combined radiotherapy-chemotherapy: lessons from the management of bone metastases or inoperable lung carcinoma | |
| Authors | V. Vassiliou, D. Vomvas, C. Christopoulos, M. Puglisi and D. Kardamakis
Department of Radiation Oncology, Medical School, University of Patras, Patras, Greece |
|
| Citation | Vassiliou, V., Vomvas, D., Christopoulos, C., Puglisi, M., Kardamakis, D.: Combined radiotherapy-chemotherapy: lessons from the management of bone metastases or inoperable lung carcinoma, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 120-121 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Radiotherapy, bone metastases, ibandronate, NSCLC, vinorelbine. | |
| Other Terms | review article | |
| Summary | Radiotherapy (RT) is an effective mode of therapy against cancer, both for radical and palliative treatments. Its effectiveness can be enhanced by pharmaceuticals such as bisphosphonates or chemotherapeutic agents (CT). Two of the combined treatments that we have introduced in our department are for patients with metastatic bone lesions, and patients with locally advanced Non Small Cell Lung Carcinoma (NSCLC). What is of uttermost importance for the administration of combined treatments is safety and toxicity. Bisphosphonates and radiotherapy have shown to have a synergistic activity bringing about significant pain relief and improvements in quality of life and physical status. The major toxicity of RT in the treatment of bone metastases is bone marrow depression. Bisphosphonates have a highly selective activity, and hence do not contribute to the toxicity caused by RT. Vinorelbine has shown to have antitumor activity against NSCLC and is capable of enhancing the efficacy of RT through its sensitizing effect. The enhanced cytotoxic activity may contribute to the local control and therapeutic response. The limiting toxicity of vinorelbine administration is bone marrow depression resulting mainly in neutropenia. In this study we present our clinical experience based on 80 patients treated with bisphosphonates and RT, and 14 patients managed with vinorelbine and RT. The toxicities noted for both of the combined treatments were within expected extent and severity. | |
| References | 1. Brown H.K., Healy J.H.: Metastatic cancer in bone. In: (De Vita VT, Hellman S, Rosenberg SA, eds) Cancer – Principles and Practice of Oncology. Pp. 2713-2729, 6th Ed., Lippincott Williams and Wilkins, Philadelphia, 2001
2. Coleman R.E.: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27: 165-176 (2001) 3. Fertil B., Malaise E.P.: Intrinsic Radiosensitivity of human cell lines is correlated with radio responsiveness of human tumors: analysis of 101 published survival curves. Int. J. Radiother. Oncol. Biol. Phys. 11: 1699-1707 (1985) 4. Hoskin P.J.: Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev. 29: 321-327 (2003) 5. Fleish H.: Bisphosphonates in Bone Disease. 4th Edition, Academic Press, San Diego CA, 2000 6. Micke O.: Ibandronate application and Irradiation in osteolytic metastases of prostate cancer. Remission 2: 11 (2001) 7. Rosen L.S., Gordon D., et al.: Zoledronic acid versus pamidronate in treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: aphase III, double blind, comparative trial. Cancer J. 7: 377- 387 (2001) 8. Sause W.T., Scott C., Taylor S., et al.: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in locoregionally advanced, unresectable NSCLC. J. Natl. Cancer Inst. 87: 198-205 (1995) 9. American Society of Clinical Oncology practice guidelines for the treatment of unresectable NSCLC. J. Clin. Oncol. 15: 2996-3018 (1997) 10. Orazio Caffo: Radiosensitization with chemotherapeutic agents. Lung Cancer 34: 81-90 (2001) 11. Gridelli C., Guida C., Barletta E., et al.: Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced NSCLC. Lung Cancer 29: 131-137 (2000) 12. Kazuya Fukuoka, et al.: Mechanism of the radiosensitization in human NSCLC cells. Lung Cancer 3001 |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|